Across TCGA pan-cancer cohorts, FAM230A Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FAM230A data layer compared with 9 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher FAM230A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM230A expression acts as an unfavorable survival marker.
ESCA are the cancer types where FAM230A Mutation most reproducibly stratifies survival.